Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$169.25

2.81 (1.69%)

07:11
01/08/18
01/08
07:11
01/08/18
07:11

Sage Therapeutics to provide pipeline update at JPMorgan Healthcare Conference

Sage Therapeutics announced that in a corporate presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CEOJeff Jonas, M.D., will discuss several components of the company's strategy to build the business for the long term by assembling the capabilities to fully develop and commercialize important medicines. His remarks will highlight three key areas of focus in the pursuit of new classes of CNS therapies: impacting novel, fundamental brain mechanisms; addressing treatment gaps with differentiated therapies; and discovering a potentially groundbreaking approach to depressive disorders. Dr. Jonas will provide additional detail on the following development programs: Brexanolone: Sage is currently focused on launch readiness and building commercial infrastructure to ensure successful commercial execution, if Sage's proprietary formulation brexanolone is approved to address postpartum depression, a common biological complication of childbirth. SAGE-217 and SAGE-324: Sage's novel, oral, next-generation positive allosteric modulators of synaptic and extra-synaptic GABAA receptors. GABA Discovery Programs: Evaluating a series of novel GABAA receptor modulators in pre-clinical development, including SAGE-689, SAGE-105, and others. NMDA Programs: Sage's novel, oral, first-in-class oxysterol-based positive allosteric modulators of the NMDA receptor. The company recently selected SAGE-904 as its second NMDA receptor positive allosteric modulator product candidate for development. Positive modulation of NMDA receptors may have potential in the treatment of a range of neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms. Sage ended 2017 with approximately $518M of cash, cash equivalents and marketable securities, including $325.7M in net proceeds from a public offering completed in November 2017. Based on its current operating plans, Sage expects that its operating expenses will increase year over year in 2018 to support continued pipeline advancement and potential product commercialization of brexanolone in PPD. Sage expects to provide specific 2018 financial guidance in Q4 and FY17 financial results announcement in February 2018.

  • 08

    Jan

SAGE Sage Therapeutics
$169.25

2.81 (1.69%)

12/08/17
RHCO
12/08/17
NO CHANGE
Target $178
RHCO
Buy
Sage Therapeutics price target raised to $178 from $116 at SunTrust
SunTrust analyst Edward Nash raised his price target on Sage Therapeutics to $178 after its positive Phase 2 trial results for SAGE-217 for moderate to severe major depressive disorder. Nash says the findings demonstrate that "rapid onset of action and durability are key differentiators for SAGE-217", also adding that safety is not a concern for the drug based on the clinical studies of both brexanolone and SAGE-217 so far. The analyst has also increased his probability of success estimates for SAGE-217 from 30% to 60% in major depressive disorder cases and from 50% to 60% in post-partum depression cases.
12/08/17
NEED
12/08/17
NO CHANGE
Target $193
NEED
Buy
Sage Therapeutics price target raised to $193 from $100 at Needham
Needham analyst Danielle Brill raised her price target on Sage Therapeutics to $193 following positive Phase 2 results of SAGE-217 in major depressive disorder cases. Brill says that given the "clear and consistent benefit" of the treatment, she has "increased confidence that '217 may have utility in a broad spectrum of mood disorders". In addition to reaching "blockbuster status", the analyst contends that '217 raises the possibility of a near term M&A approach from big pharma.
12/08/17
RAJA
12/08/17
NO CHANGE
Target $206
RAJA
Strong Buy
Sage Therapeutics price target raised to $206 from $109 at Raymond James
Raymond James analyst Laura Chico raised Sage Therapeutics' price target to $206 following positive Phase 2 results of SAGE-217 in major depressive disorder cases. Chico raised her prior market share and probability of success assumptions, as well as adding credit in postpartum depression and thinks the update de-risks that program. The analyst has a Strong Buy rating on Sage shares.
12/08/17
BMOC
12/08/17
NO CHANGE
Target $203
BMOC
Outperform
Sage Therapeutics price target raised to $203 from $112 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target on Sage Therapeutics to $203 and kept his Outperform rating after releasing Phase 2 SAGE-217 major depressive disorder data that "transforms the company". Nachman says he sees high probability of success for the treatment as it progresses to larger Phase 3 studies and calls it a "game changer" in the very large major depressive disorder / post-partum depression markets. The analyst also says the company remains an "attractive acquisition candidate".

TODAY'S FREE FLY STORIES

MDSO

Medidata

$75.53

-0.45 (-0.59%)

05:11
05/23/18
05/23
05:11
05/23/18
05:11
Recommendations
Medidata analyst commentary  »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VIRT

Virtu Financial

$29.10

-0.7 (-2.35%)

05:03
05/23/18
05/23
05:03
05/23/18
05:03
Initiation
Virtu Financial initiated  »

Virtu Financial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRO

Kronos Worldwide

$24.77

-0.165 (-0.66%)

04:59
05/23/18
05/23
04:59
05/23/18
04:59
Upgrade
Kronos Worldwide rating change  »

Kronos Worldwide upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$25.64

0.04 (0.16%)

, JWN

Nordstrom

$45.79

-0.05 (-0.11%)

04:56
05/23/18
05/23
04:56
05/23/18
04:56
Downgrade
DSW, Nordstrom rating change  »

DSW downgraded to Hold…

DSW

DSW

$25.64

0.04 (0.16%)

JWN

Nordstrom

$45.79

-0.05 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PLAB

Photronics

$9.05

0.6 (7.10%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Photronics to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TMO

Thermo Fisher

$217.88

1.2 (0.55%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Thermo Fisher to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

CAFD

8point3 Energy

$12.19

(0.00%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
8point3 Energy to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WST

West Pharmaceutical

$90.09

-0.04 (-0.04%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
West Pharmaceutical management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

FMBI

First Midwest

$26.40

0.25 (0.96%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
First Midwest management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SRDX

Surmodics

$49.10

0.8 (1.66%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Surmodics management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

OTEX

OpenText

$34.21

0.11 (0.32%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

FOMC Minutes to be…

WD

Walker & Dunlop

$56.00

-0.1 (-0.18%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

WWE

WWE

$56.88

-0.98 (-1.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BMCH

BMC Stock Holdings

$19.75

-0.7 (-3.42%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
BMC Stock Holdings management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

LOGI

Logitech

$40.86

0.15 (0.37%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Logitech management to meet with Citi »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

MTOR

Meritor

$21.94

-0.2 (-0.90%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Meritor management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Jun

GGG

Graco

$46.70

-0.64 (-1.35%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Graco management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SSRM

SSR Mining

$10.28

-0.02 (-0.19%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SSR Mining management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.05

-0.55 (-0.91%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

QTM

Quantum

$3.65

0.025 (0.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

WERN

Werner

$38.30

-0.7 (-1.79%)

, USAK

USA Truck

$23.19

-3.3 (-12.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Wolfe Research to hold a conference »

11th Annual Global…

WERN

Werner

$38.30

-0.7 (-1.79%)

USAK

USA Truck

$23.19

-3.3 (-12.46%)

LKQ

LKQ Corp.

$30.14

-0.62 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

, BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SunTrust to hold a bus tour »

Casino Bus tour travels…

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

CZR

Caesars

$12.65

-0.2 (-1.56%)

RRR

Red Rock Resorts

$34.09

-0.54 (-1.56%)

LGND

Ligand

$187.19

1.95 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SFBS

ServisFirst

$43.67

-0.01 (-0.02%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
ServisFirst management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.